Form 8-K AbbVie Inc. For: Apr 26

Go back to Form 8-K AbbVie Inc. For: Apr 26

Abbvie (ABBV) PT Lowered to $187 at Barclays

April 29, 2024 5:22 AM EDT

Barclays analyst Carter Gould lowered the price target on Abbvie (NYSE: ABBV) to $187.00 (from $195.00) while maintaining a Overweight rating.

The analyst comments "Humira erosion and transient headwinds drive reframing of '25 EPS growth, though LT profile keeps us positively biased; lowering PT to $187."

... More